A novel dietary intervention combining a standardized IBD diet (IBD-AID) with supplementation from a pea protein plant-based oral nutrition supplement (ONS) (Kate Farms Peptide 1.5) to improve protein, calorie, and nutrient intake in adult patients experiencing a Crohn's disease flare starting new immunologic therapy. Additionally, this study will include objective measures of body composition to improve nutrition status assessment and provide a more sensitive measure of intervention efficacy compared to anthropometric measures of body weight or BMI.

Inclusion Criteria:

• Moderate to severe CD as defined by physician and starting new biologic therapy
• Able and willing to complete the study procedures
• Age > 18
• Able to comply with study measures in the opinion of the investigator

Exclusion Criteria:

• Diagnosis of short bowel syndrome
• Presence of ileostomy or colostomy
• Presence of a pacemaker or any electronic implantable device
• Use of pre or probiotic supplements within 14 days of randomization
• High risk for development of refeeding syndrome
• In the opinion of the investigator would not complete the study procedures
• Patients with active implanted medical devices, e.g. cardiac pacemakers, defibrillators or patients connected to electronic life support devices
• Pregnant Patients: while the use of bioimpedance technology in pregnant patients has been shown to have no adverse effects, it has yet to be clinically validated for use with that population group
• Serious, concomitant illness that, in the opinion of the investigator would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation